Orphan Drugs Market Report and Forecast 2020-2025 With COVID-19 Update

1
Global Orphan Drugs Market Research Report
and Forecast 2020 - 2025
www.imarcgroup.com
Sales_at_imarcgroup.com
1-631-791-1145
2
About IMARC
Email sales_at_expertmarketresearch.com
Web www.expertmarketresearch.com
Phone [phone]
3
What We Do
4
REPORT OBJECTIVES Highlight
5
Report Description
According to IMARC Groups latest report, titled
Orphan Drugs Market Industry Trends, Share,
Size, Growth, Opportunity and Forecast
2020-2025,. Looking forward, IMARC Group expects
the global orphan drugs market to exhibit
moderate growth during the next five
years. Orphan drugs are used to diagnose,
prevent, and treat rare medical disorders. These
drugs aim to meet particular public health
requirements and generally have a limited
production, only for a small group of patients.
Orphan drugs help in treating several
oncological, metabolic, hematologic, immunologic,
infectious, and neurological ailments. These
ailments majorly include lymphoma, leukemia,
cystic fibrosis, glioma, pancreatic cancer,
ovarian cancer, etc.  Request for a free sample
copy of this report https//www.imarcgroup.com/or
phan-drugs-market/requestsample Market
Trends The high prevalence of cancer and other
rare genetic disorders is primarily driving the
need for orphan drugs. Several pharma companies
are focusing on developing new orphan drugs for
providing personalized therapies for patients.
Additionally, the higher approval rate of several
pipeline drugs, along with the introduction of
numerous favorable government policies to curb
the spread of various infectious diseases, is
also catalyzing the market growth. Moreover,
extensive RD activities for the development of
biological orphan drugs that can treat cancer and
minimize the damage caused to the stem cells are
further expected to drive the market for orphan
drugs in the coming years.
6
Report Description

• Orphan Drugs Market 2020-2025 Analysis and
  Segmentation
•  
• Competitive Landscape
• The competitive landscape of the market has been
  studied in the report with the detailed profiles
  of the key players operating in the market.
•  Some of these key players include
• AbbVie Inc.
• Alexion Pharmaceuticals Inc.
• Amgen Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG (Roche Holding AG)
• Jazz Pharmaceuticals Plc
• Johnson Johnson
• Merck Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited

7
Report Description

• The report has segmented the market on the basis
  of drug type, disease type, phase, top selling
  drug, distribution channel and region.
• Breakup by Drug Type
• Biological
• Non-Biological
• Breakup by Disease Type
• Oncology
• Hematology
• Neurology
• Cardiovascular
• Others
• Breakup by Phase
• Phase I
• Phase II
• Phase III
• Phase IV

8
Report Description

• Breakup by Top Selling Drugs
• Revlimid
• Rituxan
• Copaxone
• Opdivo
• Keytruda
• Imbruvica
• Avonex
• Sensipar
• Soliris
• Others
• Breakup by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others
• Breakup by Region

9
Report Description

• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

10
Report Description

• Key highlights of the report
• Market Performance (2014-2019)
• Market Outlook (2020- 2025)
• Porters Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive mapping of the competitive
  landscape
• Explore full report with table of contents
  https//www.imarcgroup.com/orphan-drugs-market
• If you need specific information that is not
  currently within the scope of the report, we will
  provide it to you as a part of the customization.
• Browse Related Report By IMARC Group
• Acne Drugs Market https//www.imarcgroup.com/acne
  -drugs-market
• Regenerative Medicine Market https//www.imarcgro
  up.com/regenerative-medicine-market

11
Report Description

• Key Questions Answered in This Report
• How has the global orphan drugs market performed
  so far and how will it perform in the coming
  years?
• What has been the impact of COVID-19 on the
  global orphan drugs market?
• What are the key regional markets?
• What is the breakup of the market based on the
  drug type?
• What is the breakup of the market based on the
  disease type?
• What is the breakup of the market based on the
  phase?
• What is the breakup of the market based on the
  top selling drugs?
• What is the breakup of the market based on the
  distribution channel?
• What are the various stages in the value chain of
  the industry?
• What are the key driving factors and challenges
  in the industry?
• What is the structure of the global orphan drugs
  market and who are the key players?
• What is the degree of competition in the industry?

12
Table of Contents
13
Table of Contents
1   Preface2    Scope and Methodology     2.1  
 Objectives of the Study    2.2  
 Stakeholders    2.3    Data Sources       
2.3.1    Primary Sources        2.3.2  
 Secondary Sources    2.4    Market Estimation 
      2.4.1    Bottom-Up Approach        2.4.2  
 Top-Down Approach    2.5    Forecasting
Methodology3    Executive Summary4  
 Introduction    4.1    Overview    4.2    Key
Industry Trends5    Global Orphan Drugs Market 
  5.1    Market Overview    5.2    Market
Performance    5.3    Impact of COVID-19    5.4
   Market Forecast6    Market Breakup by Drug
Type    6.1    Biological        6.1.1 Market
Trends        6.1.2 Market Forecast    6.2  
 Non-Biological        6.2.1 Market Trends     
                
14
Table of Contents
    7     6.2.2 Market Forecast7    Market
Breakup by Disease Type    7.1    Oncology     
  7.1.1 Market Trends        7.1.2 Market
Forecast    7.2    Hematology        7.2.1
Market Trends        7.2.2 Market Forecast   
7.3    Neurology        7.3.1 Market Trends   
    7.3.2 Market Forecast    7.4  
 Cardiovascular        7.4.1 Market Trends     
  7.4.2 Market Forecast    7.5    Others       
7.5.1 Market Trends        7.5.2 Market
Forecast8    Market Breakup by Phase    8.1  
 Phase I        8.1.1 Market Trends       
8.1.2 Market Forecast    8.2    Phase II       
8.2.1 Market Trends        8.2.2 Market
Forecast    8.3    Phase III               
        
15
Table of Contents
8.3.1 Market Trends        8.3.2 Market
Forecast    8.4    Phase IV        8.4.1 Market
Trends        8.4.2 Market Forecast9    Market
Breakup by Top Selling Drugs    9.1  
 Revlimid        9.1.1 Market Trends       
9.1.2 Market Forecast    9.2    Rituxan       
9.2.1 Market Trends        9.2.2 Market
Forecast    9.3    Copaxone        9.3.1 Market
Trends        9.3.2 Market Forecast    9.4  
 Opdivo        9.4.1 Market Trends        9.4.2
Market Forecast    9.5    Keytruda        9.5.1
Market Trends        9.5.2 Market Forecast   
9.6    Imbruvica        9.6.1 Market Trends   
    9.6.2 Market Forecast    9.7    Avonex     
  9.7.1 Market Trends                          
                         
16
Table of Contents
9.7.2 Market Forecast    9.8    Sensipar     
  9.8.1 Market Trends        9.8.2 Market
Forecast    9.9    Soliris        9.9.1 Market
Trends        9.9.2 Market Forecast    9.10  
 Others        9.10.1 Market Trends       
9.10.2 Market Forecast10    Market Breakup by
Distribution Channel    10.1    Hospital
Pharmacy        10.1.1 Market Trends       
10.1.2 Market Forecast    10.2    Retail
Pharmacy        10.2.1 Market Trends       
10.2.2 Market Forecast    10.3    Online
Stores        10.3.1 Market Trends       
10.3.2 Market Forecast    10.4    Others       
10.4.1 Market Trends        10.4.2 Market
Forecast11    Market Breakup by Region    11.1
   North America        11.1.1 United States   
                                                
     
17
Table of Contents
11.1.1.1 Market Trends           11.1.1.2
Market Forecast        11.1.2 Canada         
 11.1.2.1 Market Trends           11.1.2.2
Market Forecast    11.2    Asia Pacific       
11.2.1 China           11.2.1.1 Market Trends 
         11.2.1.2 Market Forecast        11.2.2
Japan           11.2.2.1 Market Trends         
 11.2.2.2 Market Forecast        11.2.3 India 
         11.2.3.1 Market Trends         
 11.2.3.2 Market Forecast        11.2.4 South
Korea           11.2.4.1 Market Trends         
 11.2.4.2 Market Forecast        11.2.5
Australia           11.2.5.1 Market Trends     
     11.2.5.2 Market Forecast        11.2.6
Indonesia           11.2.6.1 Market Trends     
     11.2.6.2 Market Forecast        11.2.7
Others           11.2.7.1 Market Trends       
               
18
Table of Contents
11.2.7.2 Market Forecast    11.3    Europe     
  11.3.1 Germany           11.3.1.1 Market
Trends           11.3.1.2 Market Forecast     
  11.3.2 France           11.3.2.1 Market
Trends           11.3.2.2 Market Forecast     
  11.3.3 United Kingdom           11.3.3.1
Market Trends           11.3.3.2 Market
Forecast        11.3.4 Italy           11.3.4.1
Market Trends           11.3.4.2 Market
Forecast        11.3.5 Spain           11.3.5.1
Market Trends           11.3.5.2 Market
Forecast        11.3.6 Russia         
 11.3.6.1 Market Trends           11.3.6.2
Market Forecast        11.3.7 Others         
 11.3.7.1 Market Trends           11.3.7.2
Market Forecast    11.4    Latin America       
11.4.1 Brazil           11.4.1.1 Market Trends 
                                                
       
19
Table of Contents
11.4.1.2 Market Forecast        11.4.2 Mexico 
         11.4.2.1 Market Trends         
 11.4.2.2 Market Forecast        11.4.3 Others 
         11.4.3.1 Market Trends         
 11.4.3.2 Market Forecast    11.5    Middle East
and Africa        11.5.1 Market Trends       
11.5.2 Market Breakup by Country        11.5.3
Market Forecast12    SWOT Analysis    12.1  
 Overview    12.2    Strengths    12.3  
 Weaknesses    12.4    Opportunities    12.5  
 Threats13    Value Chain Analysis14    Porters
Five Forces Analysis    14.1    Overview   
14.2    Bargaining Power of Buyers    14.3  
 Bargaining Power of Suppliers    14.4    Degree
of Competition    14.5    Threat of New
Entrants    14.6    Threat of Substitutes15  
 Price Analysis                  
20
Table of Contents
 16    Competitive Landscape    16.1    Market
Structure    16.2    Key Players    16.3  
 Profiles of Key Players        16.3.1    AbbVie
Inc.           16.3.1.1 Company Overview       
   16.3.1.2 Product Portfolio          
 16.3.1.3 Financials           16.3.1.4 SWOT
Analysis        16.3.2    Alexion
Pharmaceuticals Inc.           16.3.2.1 Company
Overview           16.3.2.2 Product Portfolio  
         16.3.2.3 Financials           16.3.2.4
SWOT Analysis        16.3.3    Amgen Inc.     
     16.3.2.1 Company Overview         
 16.3.2.2 Product Portfolio            16.3.2.3
Financials           16.3.2.4 SWOT Analysis   
    16.3.4    Biogen Inc.           16.3.4.1
Company Overview           16.3.4.2 Product
Portfolio            16.3.4.3 Financials       
   16.3.4.4 SWOT Analysis        16.3.5  
 Bristol Myers Squibb Company           16.3.5.1
Company Overview                    
21
Table of Contents
 16.3.5.2 Product Portfolio            16.3.5.3
Financials           16.3.5.4 SWOT Analysis   
    16.3.6    F. Hoffmann-La Roche AG (Roche
Holding AG)           16.3.6.1 Company
Overview           16.3.6.2 Product Portfolio  
         16.3.6.3 SWOT Analysis        16.3.7  
 Jazz Pharmaceuticals Plc           16.3.7.1
Company Overview           16.3.7.2 Product
Portfolio            16.3.7.3 Financials       
   16.3.7.4 SWOT Analysis        16.3.8  
 Johnson Johnson            16.3.8.1 Company
Overview           16.3.8.2 Product Portfolio 
         16.3.8.3 Financials           16.3.8.4
SWOT Analysis        16.3.9    Merck Co.
Inc.           16.3.9.1 Company Overview       
   16.3.9.2 Product Portfolio          
 16.3.9.3 Financials           16.3.9.4 SWOT
Analysis        16.3.10    Novartis AG         
 16.3.10.1 Company Overview           16.3.10.2
Product Portfolio            16.3.10.3
Financials                               
22
Table of Contents
16.3.10.4 SWOT Analysis        16.3.11    Pfizer
Inc.           16.3.11.1 Company Overview     
     16.3.11.2 Product Portfolio          
 16.3.11.3 Financials           16.3.11.4 SWOT
Analysis        16.3.12    Sanofi S.A.        
   16.3.12.1 Company Overview         
 16.3.12.2 Product Portfolio          
 16.3.12.3 Financials           16.3.12.4 SWOT
Analysis        16.3.13    Takeda Pharmaceutical
Company Limited            16.3.13.1 Company
Overview           16.3.13.2 Product
Portfolio            16.3.13.3 Financials     
     16.3.13.4 SWOT Analysis        16.3.14  
 Teva Pharmaceutical Industries Ltd         
 16.3.14.1 Company Overview           16.3.14.2
Product Portfolio            16.3.14.3
Financials           16.3.14.4 SWOT Analysis   
                           
23
Report FAQs
Team Profile
Team Profile
24
Team Profile
Growing team of 150 employees with deep market
knowledge
Engineers and Post Graduates Account for 75 of
our Team
Over 1000 Independent Consultants from different
sectors
Talents from some of the top universities
modelling specialists with unmatched expertise in
quantitative research
Individuals with experience in specific
industries and having sound knowledge of targeted
functional areas
Commercial and non-commercial relationships with
some of the top research institutes
25
Report FAQs
Words From Client
26
We have been working with IMARC Group for over
two years now. I must say that the word
impossible doesnt seems to appear in their
dictionary,. These guys can provide data for any
market in any country. I have been given them
challenging assignments to work upon and have
been quite impressed with their approach and
results. -Global
Procurement Technology Manager Global FMCG Giant
IMARC Group has great domain expertise and
knowledge base provided all the inputs necessary
for us to define the path forward and launch our
diagnostic successfully in the market where other
players were always afraid before investing.

-Vice President Marketing European
Diagnostic Company
We were really impressed with their research
findings on the South India dairy market. The
innovative idea suggested by them have given us
altogether different aspect to look at the
problem. We started with them on small project
but now thinking on doing more strategic project
with them.

-National Manager (Marketing) Indian Diary Giant
Words From Client
IMARC Group helped us with the outsourcing of a
major part of clinical trials to India. In the
beginning we were skeptic of this idea. But the
success achieved from this strategy is driving us
to outsource other verticals of our business to
low cost destinations - Member of Board of
Managing Director Global Pharmaceutical Giant
Working with IMARC Group has been a great
experience. They were able to provide us with a
comprehensive business report on the India
wastewater treatment market. The finding from the
reports are played a major role in our business
strategies and future decision making
-Senior Vice President Major Indian
Effluent Treatment Company
27
Report FAQs
Report FAQs
28
Report FAQs
01
02
03
04
05
29
Report FAQs
06
07
08
09
30
SOME OF OUR KEY CUSTOMERS